{"id":"cetuximab-wkly","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Acneiform rash"},{"rate":"25–30","effect":"Diarrhea"},{"rate":"20–25","effect":"Nausea"},{"rate":"15–20","effect":"Fatigue"},{"rate":"3–5","effect":"Infusion reactions"},{"rate":"13–17","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab binds to EGFR on the surface of cancer cells, preventing ligand-induced receptor activation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis. The weekly formulation (cetuximab wkly) refers to a dosing schedule optimized for patient convenience while maintaining therapeutic efficacy.","oneSentence":"Cetuximab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:42.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (KRAS wild-type)"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer (EGFR-expressing)"}]},"trialDetails":[{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux"],"phase":"phase_3","status":"active","brandName":"Cetuximab wkly","genericName":"Cetuximab wkly","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation and survival. Used for Metastatic colorectal cancer (KRAS wild-type), Head and neck squamous cell carcinoma, Non-small cell lung cancer (EGFR-expressing).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}